Brief: Cytodyn Files Trial Protocol With FDA To Treat COVID-19 Patients With Leronlimab
01/04/2020 11:19
April 1 (Reuters) - Cytodyn Inc CYDY.PK :
* CYTODYN FILES A CLINICAL TRIAL PROTOCOL WITH THE FDA TO
TREAT
SEVERELY ILL COVID-19 PATIENTS WITH LERONLIMAB WHERE THE PRIMARY
ENDPOINT IS MORTALITY RATE AT TWO WEEKS
Source text for Eikon: ID:nGNX6nWq3n
Further company coverage: CYDY.PK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Cytodyn
See all newsBrief: Cytodyn Appoints Robert E. Hoffman As Chief Executive Officer
Brief: Cytodyn Closes $17.5 Million Financing To Fund Continued Development Of Leronlimab
Brief: CytoDyn Inc Files For Offering Of Up To 120 Million Shares Of Common Stock By Selling Stockholder - SEC Filing
Brief: Cytodyn Files For Mixed Shelf Of Up To $100 Million - SEC Filing
Brief: CytoDyn Announces First Patient Dosed in Phase II Oncology Trial in Colorectal Cancer